The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Hyperprolactinemia and Prolactinomas
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ezzat, S., Zheng, L., Zhu, X.-F., Wu, G. E., & Asa, S. L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14036 · Cited by 179
RetractedProlactin: structure, function, and regulation of secretion
Freeman, M. E., Kanyicska, B., Lerant, A., & Nagy, G. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.4.1523 · Cited by 2,457
Bole-Feysot, C., Goffin, V., Edery, M., Binart, N., & Kelly, P. A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.3.0334 · Cited by 1,938
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Criteria for Cure of Acromegaly: A Consensus Statement
Giustina, A. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.526 · Cited by 987
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationStratakis, C. A., Kirschner, L. S., & Carney, J. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4041 · Cited by 826
Advances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
Research works printed but not linked: 42
- Bernichtein, 2001, S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist, Endocrinology, 142, 3950, 10.1210/endo.142.9.8369 · doi:10.1210/endo.142.9.8369
- Wu, 2003, Different biological effects of unmodified PRL and a molecular mimic of phosphorylated PRL involve different signaling pathways, Biochemistry, 42, 7561, 10.1021/bi034217s · doi:10.1021/bi034217s
- De Marinis, 2000, Effects of galanin on growth hormone and PRL secretion in anorexia nervosa, Metabolism, 49, 155, 10.1016/S0026-0495(00)91091-6 · doi:10.1016/s0026-0495(00)91091-6
- Lafuente, 2005, Toxic effects of cadmium on the regulatory mechanism of dopamine and serotonin on PRL secretion in adult male rats, Toxicol Lett, 155, 87, 10.1016/j.toxlet.2004.08.011 · DOI
- Niu, 2004, Neurobehavioral functions, serum PRL and plasma renin activity of manganese-exposed workers, Int J Immunopathol Pharmacol, 17, 17, 10.1177/03946320040170S204 · doi:10.1177/03946320040170s204
- Lucchini, 2000, Assessment of neurobehavioral performance as a function of current and cumulative occupational lead exposure, Neurotoxicology, 21, 805
- Alessio, 2006, Prolactin changes as a consequence of chemical exposure, Environ Health Perspect, 114, A573, 10.1289/ehp.114-a573 · doi:10.1289/ehp.114-a573
- Waschek, 1987, Barium distinguishes separate calcium targets for synthesis and secretion of peptides in neuroendocrine cells, Biochem Biophys Res Commun, 146, 495, 10.1016/0006-291X(87)90556-0 · doi:10.1016/0006-291x(87)90556-0
- Vrkljan, 2006, Incidence of pituitary tumors in the human population of Croatia, Coll Antropol, 30, 157
- Zargar, 2004, Clinical and endocrine aspects of pituitary tumors, Saudi Med J, 25, 1428
- Fideleff, 2000, Peripubertal prolactinoma: clinical presentation and long-term outcome with different therapeutic approaches, J Pediatr Endocrinol Metab, 13, 261, 10.1515/JPEM.2000.13.3.261 · DOI
- Mindermann, 1995, Pituitary adenomas in childhood and adolescence, J Pediatr Endocrinol Metab, 8, 79, 10.1515/JPEM.1995.8.2.79 · doi:10.1515/jpem.1995.8.2.79
- Daly, 2006, Clinical characterization of familial isolated pituitary adenomas, J Clin Endocrinol Metab, 91, 3316, 10.1210/jc.2005-2671 · doi:10.1210/jc.2005-2671
- Karga, 1992, Ras mutations in human pituitary tumors, J Clin Endocrinol Metab, 74, 914, 10.1210/jcem.74.4.1312542 · doi:10.1210/jcem.74.4.1312542
- Cristina, 2007, PTTG expression in different experimental and human prolactinoma in relation to dopaminergic control of lactotropes, Mol Cancer, 6, 1, 10.1186/1476-4598-6-4 · doi:10.1186/1476-4598-6-4
- Horwitz, 2003, Human pituitary tumor-transforming gene (PTTG1) motif suppresses PRL expression, Mol Endocrinol, 17, 600, 10.1210/me.2001-0006 · doi:10.1210/me.2001-0006
- Sigala, 2004, Increased serum concentration of nerve growth factor in patients with microprolactinoma, Neuropeptides, 38, 21, 10.1016/j.npep.2003.11.002 · doi:10.1016/j.npep.2003.11.002
- Smith, 2007, Technology insight: measuring PRL in clinical samples, Nat Clin Pract Endocrinol Metab, 3, 279, 10.1038/ncpendmet0447 · DOI
- Quinn, 2006, Determination of ultrafilterable PRL: elimination of macroprolactin interference with a monomeric PRL-selective sample pretreatment, Arch Pathol Lab Med, 130, 1807, 10.5858/2006-130-1807-DOUPEO · doi:10.5858/2006-130-1807-doupeo
- Hauache, 2002, Screening for macroprolactinaemia and pituitary imaging studies, Clin Endocrinol (Oxf), 57, 327, 10.1046/j.1365-2265.2002.01586.x · doi:10.1046/j.1365-2265.2002.01586.x
- Ambrosi, 1980, PRL and sexual function, JAMA, 244, 2608, 10.1001/jama.1980.03310230014010 · doi:10.1001/jama.1980.03310230014010
- Orrego, 2000, Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine, Pituitary, 3, 189, 10.1023/A:1011412028660 · doi:10.1023/a:1011412028660
- Wass, 2006, When to discontinue treatment of prolactinoma?, Nat Clin Pract Endocrinol Metab, 2, 298, 10.1038/ncpendmet0162 · doi:10.1038/ncpendmet0162
- Bronstein, 2006, Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy, Nat Clin Pract Endocrinol Metab, 2, 130, 10.1038/ncpendmet0135 · doi:10.1038/ncpendmet0135
- Crosignani, 1978, Antiserotonin treatment of hyperprolactinemic amenorrhea: long-term follow-up with metergoline, methysergide, and cyproheptadine, Am J Obstet Gynecol, 132, 307, 10.1016/0002-9378(78)90898-0 · doi:10.1016/0002-9378(78)90898-0
- Bohnet, 1986, Treatment of hyperprolactinemic amenorrhea with Metergoline, Obstet Gynecol, 67, 249, 10.1097/00006250-198602000-00016 · doi:10.1097/00006250-198602000-00016
- Weiss, 1983, Bromocriptine treatment of PRL-secreting tumors: surgical implications, Neurosurgery, 12, 640, 10.1227/00006123-198306000-00008 · doi:10.1227/00006123-198306000-00008
- Kissner, 1980, Side effects of bromocriptine, N Engl J Med, 302, 749, 10.1056/NEJM198003273021313 · doi:10.1056/nejm198003273021313
- Pearson, 1981, Mental disorders from low-dose bromocriptine, N Engl J Med, 305, 173, 10.1056/NEJM198107163050321 · doi:10.1056/nejm198107163050321
- Baskin, 1982, CSF rhinorrhea after bromocriptine for prolactinoma, N Engl J Med, 306, 178, 10.1056/NEJM198201213060322 · doi:10.1056/nejm198201213060322
- Franks, 1981, Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment, Lancet, 2, 659, 10.1016/S0140-6736(81)90997-1 · doi:10.1016/s0140-6736(81)90997-1
- Giusti, 1994, A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients, J Endocrinol Invest, 17, 51, 10.1007/BF03344963 · doi:10.1007/bf03344963
- Jaquet, 1999, Quantitative and functional expression of somatostatin receptor subtypes in human prolactinoma, J Clin Endocrinol Metab, 84, 3268
- Jaquet, 2005, Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and PRL secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy, Eur J Endocrinol, 153, 135, 10.1530/eje.1.01950 · doi:10.1530/eje.1.01950
- Cappabianca, 2004, Endoscopic endonasal transsphenoidal surgery, Neurosurgery, 55, 933, 10.1227/01.NEU.0000137330.02549.0D · doi:10.1227/01.neu.0000137330.02549.0d
- Thomson, 1994, Ten year follow up of microprolactinoma treated by transsphenoidal surgery, BMJ, 309, 1409, 10.1136/bmj.309.6966.1409 · doi:10.1136/bmj.309.6966.1409
- Amar, 2002, Predictive value of serum PRL levels measured immediately after transsphenoidal surgery, J Neurosurg, 97, 307, 10.3171/jns.2002.97.2.0307 · doi:10.3171/jns.2002.97.2.0307
- Landolt, 1982, Bromocriptine: does it jeopardise the result of later surgery for prolactinoma?, Lancet, 2, 657, 10.1016/S0140-6736(82)92756-8 · doi:10.1016/s0140-6736(82)92756-8
- Fahlbusch, 1984, Influence of preoperative bromocriptine therapy on success of surgery for microprolactinoma, Lancet, 2, 520, 10.1016/S0140-6736(84)92596-0 · doi:10.1016/s0140-6736(84)92596-0
- Kuo, 2004, Gamma knife radiosurgery for benign cavernous sinus tumors: quantitative analysis of treatment outcomes, Neurosurgery, 54, 1385, 10.1227/01.NEU.0000124750.13721.94 · doi:10.1227/01.neu.0000124750.13721.94
- Landolt, 2000, Gamma knife radiosurgery for prolactinoma, J Neurosurg, 93, 14, 10.3171/jns.2000.93.supplement_3.0014 · doi:10.3171/jns.2000.93.supplement_3.0014
- Ahmed, 1992, Macroprolactinoma with suprasellar extension: effect of bromocriptine withdrawal during one or more pregnancies, Fertil Steril, 58, 492, 10.1016/S0015-0282(16)55250-9 · doi:10.1016/s0015-0282(16)55250-9
Cited by
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844
Self-citationClinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Evaluation and Management of Testosterone Deficiency: AUA Guideline
Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2018.03.115 · Cited by 766
Petersenn, S., Fleseriu, M., Casanueva, F. F., Giustina, A., Biermasz, N., Biller, B. M. K., Bronstein, M., Chanson, P., Fukuoka, H., Gadelha, M., et al. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00886-5 · Cited by 411
Self-citationPeuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
Clinical Biology of the Pituitary Adenoma
Melmed, S., Kaiser, U. B., Lopes, M. B., Bertherat, J., Syro, L. V., Raverot, G., Reincke, M., Johannsson, G., Beckers, A., Fleseriu, M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac010 · Cited by 321
Self-citationMazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Self-citationVertebral fractures in males with prolactinoma
Mazziotti, G., Porcelli, T., Mormando, M., De Menis, E., Bianchi, A., Mejia, C., Mancini, T., De Marinis, L., & Giustina, A. (2011) · Endocrine · doi:10.1007/s12020-011-9462-5 · Cited by 109
Self-citationMazziotti, G., Mancini, T., Mormando, M., De Menis, E., Bianchi, A., Doga, M., Porcelli, T., Vescovi, P. P., De Marinis, L., & Giustina, A. (2011) · Pituitary · doi:10.1007/s11102-011-0293-4 · Cited by 98
Self-citationTreatment of Cushing disease: overview and recent findings
Giustina, A. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s12952 · Cited by 66
Self-citationPrevalence and predictors of hyperprolactinemia in subclinical hypothyroidism
Sharma, L. K., Sharma, N., Gadpayle, A. K., & Dutta, D. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.07.012 · Cited by 58
Montejo, Á. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., del Pino, J., García Escudero, M. A., García Rizo, C., González-Pinto, A., et al. (2016) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2015.11.003 · Cited by 55
Metadata
- Authors
- Mancini, T., Casanueva, F. F., & Giustina, A.
- Venue
- Endocrinology and Metabolism Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 37
- Issue
- 1
- Pages
- 67-99
- ISSN
- 0889-8529 (ISSN-L)
- OpenAlex
- W2073194318
- Cited by
- 256
- References
- 157
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.